Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tanvex BioPharma's Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1,456.0 Mil. Therefore, Tanvex BioPharma's EV-to-EBIT ratio for today is -8.02.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Tanvex BioPharma's Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1,089.2 Mil. Therefore, Tanvex BioPharma's EV-to-EBITDA ratio for today is -10.71.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Tanvex BioPharma's Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$401.0 Mil. Therefore, Tanvex BioPharma's EV-to-Revenue ratio for today is 29.10.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Tanvex BioPharma's Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1,675.6 Mil. Therefore, Tanvex BioPharma's EV-to-FCF ratio for today is -6.96.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Tanvex BioPharma (TPE:6541) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,456.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,089.2 Mil.
Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$401.0 Mil.
Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,005.4 Mil.
Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil.
Tanvex BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,675.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma Enterprise Value Related Terms
Tanvex BioPharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Tanvex BioPharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Tanvex BioPharma's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$11,670.1 Mil mean?
Tanvex BioPharma (TPE:6541) has a Enterprise Value of NT$11,670.1 Mil as of Jul. 05, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tanvex BioPharma and its competitors.
Is Tanvex BioPharma's Enterprise Value too high?
Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Enterprise Value compare to VRTX and REGN?
Tanvex BioPharma's Enterprise Value of NT$11,670.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current Enterprise Value is NT$11,670.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current Enterprise Value is NT$11,670.1 Mil. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Enterprise Value is NT$11,670.1 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?
Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued.
The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61.
GuruFocus considers Tanvex BioPharma to be Possible Value Trap.
Key valuation signals for TPE:6541:
Enterprise Value: NT$11,670.1 Mil
GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score
Get the complete analysis for TPE:6541
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
